QIPB in Inguinal Hernia
Effect of the Quadro-Iliac Plane Block on Quality of Recovery Following Laparoscopic Inguinal Hernia Surgery: A Prospective, Randomized, Controlled, Double-Blind, Multicenter Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Konya, Turkey (Türkiye)
- Recruiting
- Konya City Hospital
-
Contact:
- Muhammed H SATICI, M.D
- Phone Number: +90 5455636333
- Email: halit_satici@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 18-65 years
- Undergoing elective,
- unilateral laparoscopic inguinal hernia repair
- Receiving general anesthesia
Exclusion Criteria:
- Patients who refuse to provide consent
- Patients with contraindications to regional anesthesia
- Patients with impaired consciousness
- Patients with coagulopathy
- Patients with infections at the block site
- Emergency cases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: control group
All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).
Rescue analgesia (IV tramadol 1 mg/kg) will be administered if Numerical rating scale scores are ≥3.
IV ondansetron (4 mg) will be given for nausea and vomiting.
|
Patients in Group Q will be placed in the lateral position.
A low-frequency convex transducer and a 100-mm block needle will be used.
Following sterilization, the transducer will be placed parasagittally at the distal attachment of the quadratus lumborum muscle to the iliac crest.
The iliac crest and quadratus lumborum muscle will be visualized, with the erector spinae muscle above and the psoas major muscle below.
Using an in-plane technique, the needle will be directed toward the iliac crest.
After confirmation with 5 mL of isotonic sodium chloride, 20 mL of 0.25% bupivacaine will be injected incrementally with intermittent aspiration.
The same procedure will be applied to the other party.
A total of 40 mL of 0.25% bupivacaine will be administered.
|
|
Active Comparator: Quadro iliac plane block
All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).
Rescue analgesia (IV tramadol 1 mg/kg) will be administered if Numerical rating scale scores are ≥3.
IV ondansetron (4 mg) will be given for nausea and vomiting.
Group Q patients will receive quadro iliac plane block in addition to standard analgesia.
|
All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary outcome is the QoR-15 score (0-150 point) at 24 hours postoperatively.
Time Frame: 24 hours
|
The primary outcome is the QoR-15 score (0-150 point) at 24 hours postoperatively.
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- QIPB İnguinal hernia
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.